OncoCyte logo

OncoCyteNASDAQ: OCX

Profile

Sector:

Healthcare

Country:

United States

IPO:

30 December 2015

Next earnings report:

11 April 2025

Last dividends:

N/A

Next dividends:

N/A
$45.62 M
-81%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector
-16%vs. 3y high
79%vs. sector
-38%vs. 3y high
94%vs. sector

Price

regular market | 38 min ago
$2.71+$0.05(+1.81%)

Dividend

No data over the past 3 years
$115.00 K$100.00 K
$115.00 K-$13.49 M

Analysts recommendations

Institutional Ownership

OCX Latest News

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
globenewswire.com06 November 2024 Sentiment: NEUTRAL

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes.

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
prismmediawire.com06 November 2024 Sentiment: NEUTRAL

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m.

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
prismmediawire.com16 October 2024 Sentiment: POSITIVE

IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire –  Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
globenewswire.com16 October 2024 Sentiment: POSITIVE

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
prismmediawire.com08 October 2024 Sentiment: POSITIVE

IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
globenewswire.com08 October 2024 Sentiment: POSITIVE

Results published in peer-reviewed journal , Clinical Cancer Research Study validates DetermaIO's utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp.

Oncocyte Signs Leading Transplant Centers in US and Germany
prismmediawire.com02 October 2024 Sentiment: POSITIVE

IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany.

Oncocyte Signs Leading Transplant Centers in US and Germany
globenewswire.com02 October 2024 Sentiment: POSITIVE

IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany. Both have entered into agreements with the Company to utilize GraftAssure™, the Company's research-use-only assay (“GraftAssure”) that can detect early evidence of graft organ damage in patients' blood.

Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
prismmediawire.com12 August 2024 Sentiment: POSITIVE

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results
prismmediawire.com08 August 2024 Sentiment: POSITIVE

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders.

  • 1(current)

What type of business is OncoCyte?

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

What sector is OncoCyte in?

OncoCyte is in the Healthcare sector

What industry is OncoCyte in?

OncoCyte is in the Diagnostics & Research industry

What country is OncoCyte from?

OncoCyte is headquartered in United States

When did OncoCyte go public?

OncoCyte initial public offering (IPO) was on 30 December 2015

What is OncoCyte website?

https://www.oncocyte.com

Is OncoCyte in the S&P 500?

No, OncoCyte is not included in the S&P 500 index

Is OncoCyte in the NASDAQ 100?

No, OncoCyte is not included in the NASDAQ 100 index

Is OncoCyte in the Dow Jones?

No, OncoCyte is not included in the Dow Jones index

When was OncoCyte the previous earnings report?

No data

When does OncoCyte earnings report?

The next expected earnings date for OncoCyte is 11 April 2025